A Phase 1, Single Center, Randomized, Controlled Platform Study Validating the Use of Candin As a Challenge Agent in Healthy Volunteers or Patients Given Concomitant Approved Interventions
Latest Information Update: 23 Jun 2021
At a glance
- Drugs Belimumab (Primary) ; Candida antigen (Primary)
- Indications Delayed hypersensitivity
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 17 Jun 2021 Status changed from active, no longer recruiting to completed.
- 10 May 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2021 Planned primary completion date changed from 25 Feb 2021 to 6 May 2021.